Alpha Tau Medical Ltd. (Alpha Tau), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital Corp. (Nasdaq: HCCC) (HCCC), a special purpose acquisition company, have announced the successful closing of the previously announced business combination (the Business Combination). The combined company will continue to be led by Alpha Tau's existing management team. Alpha Tau's ordinary shares and warrants are expected to begin trading on Tuesday, March 8, 2022, on Nasdaq under the ticker symbols "DRTS" and "DRTSW," respectively.
Latham & Watkins LLP represented Alpha Tau in the deSPAC transaction with an M&A team led by New York partner Eyal Orgad and New York counsel Michael Vardanian, with New York associate Charles Shier, and a capital markets team led by London partner Joshua Kiernan and New York partner Nathan Ajiashvili, with London counsel Michael Rosenberg and New York associate Danny Shulman. Advice was provided on tax matters by Century City partner Pardis Zomorodi, with New York associate Sam Yang.